Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Consolidated Net Income: 2020-2025

Historic Consolidated Net Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $215.7 million.

  • Apellis Pharmaceuticals' Consolidated Net Income rose 475.46% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Consolidated Net Income stood at $215.7 million, which was up 611.35% from -$42.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Consolidated Net Income registered a high of $215.7 million during Q3 2025, and its lowest value of -$219.2 million during Q2 2021.
  • Its 3-year average for Consolidated Net Income is -$58.7 million, with a median of -$66.5 million in 2024.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 222.56% in 2021, then skyrocketed by 475.46% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$147.9 million in 2021, then declined by 12.21% to -$166.0 million in 2022, then surged by 46.64% to -$88.6 million in 2023, then surged by 58.99% to -$36.3 million in 2024, then soared by 475.46% to $215.7 million in 2025.
  • Its Consolidated Net Income stands at $215.7 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$92.2 million for Q1 2025.